WELLGISTICS HEALTH, INC. OFFICIALLY CHANGES CORPORATE NAME TO DATAMEDS AI, INC.

Rhea-AI Summary

DataMeds AI (NASDAQ:MEDS), formerly Wellgistics Health (NASDAQ:WGRX), announced completion of its corporate name change and will begin trading under the new ticker MEDS on the NASDAQ Capital Market on July 22, 2026.

The Health IT company integrates its EinsteinRx AI pharmacy dispensing platform with the PharmacyChain blockchain smart contracts system inside the Health Lives Here app. DataMeds plans to build a vertically aligned healthcare ecosystem, initially targeting GLP-1-associated muscle loss and Long COVID, consolidating patient health data on a proprietary blockchain and enabling patient participation in data-transaction revenue.

Market reaction after corporate name change: WGRX +29.89% in the Jul 21 session

+29.89% 24.2x vol

22 alerts

+29.89% Session close to close

+33.7% Peak in 1 hr 4 min

$6.81M Market Cap

24.2x Rel. Volume

In the Jul 21 session, WGRX gained 29.89%, reflecting a significant positive market reaction. Argus tracked a peak move of +33.7% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 24.2x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +29.9% in the session following this news. AI-tagged history recorded a 6.64% move ...

Analysis

The stock surged +29.9% in the session following this news. AI-tagged history recorded a 6.64% move for news_id 1075231, providing a direct precedent for this completed rebrand. The effective S-3 shelf permits up to $200,000,000 of securities, a disclosed financing risk; short positioning was low.

Key Figures

Announcement date: July 21, 2026 New trading date: July 22, 2026

2 metrics

Announcement date July 21, 2026 Corporate name change announcement

New trading date July 22, 2026 MEDS ticker begins trading on Nasdaq

Previous AI Reports

5 past events · Latest: Jun 26 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 26	proposed name change	Positive	+6.6%	Proposed DataMeds AI name and vertically integrated healthcare ecosystem plans
Feb 18	mental health AI investment	Positive	+0.3%	Strategic investment expanded patient engagement and AI-related healthcare initiatives
Nov 26	meme coin distribution	Neutral	+14.8%	Shareholder distribution plan for the Dream Bowl 2026 Meme Coin
Nov 12	EinsteinRx launch	Positive	-3.4%	Prescription management hub launched for healthcare infrastructure integration
Oct 27	smart contract agreement	Positive	-28.7%	PharmacyChain development agreement targeted blockchain prescription tracking

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-tagged announcements produced mixed reactions, with three divergences and an average move of -2.06%.

Key Terms

blockchain, smart contracts, glp-1

3 terms

blockchain technical

"through a proprietary blockchain"

A blockchain is a digital record-keeping system that securely stores information across many computers, making it difficult to alter or tamper with. Think of it like a shared, unchangeable ledger that everyone can see and verify, ensuring transparency and trust. For investors, this technology offers a way to securely track transactions and assets without relying on a central authority, potentially reducing costs and increasing security.

View in glossary

smart contracts technical

"patented pharmacy smart contracts platform PharmacyChain"

Self-executing digital agreements whose terms are written as code and stored on a distributed ledger so they run automatically when preset conditions are met — like a vending machine that releases a snack only after you insert the right coins. Investors care because smart contracts can speed up transactions, cut middlemen, reduce errors and fraud, and create new ways to issue, trade or enforce financial assets, which affects costs, risk and regulatory oversight.

View in glossary

glp-1 medical

"initially targeting GLP-1-associated muscle loss"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Leading Health IT Company's Rebranding Reflects Updated Healthcare Ecosystem Aligned with AI Integration to Optimize Patient Control of Healthcare Data

TAMPA, Fla., July 21, 2026 /PRNewswire/ -- Wellgistics Health, Inc., (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx^™ into patented pharmacy smart contracts platform PharmacyChain^™, today announced that it has officially completed its name change to  DataMEDS AI, Inc. ("DataMEDS" or  "the Company"). Simultaneous with this announcement, the Company announced that it will begin trading under the stock symbol 'MEDS' on the NASDAQ Capital Market stock exchange on Wednesday, July 22, 2026.

DataMeds aims to deliver a vertically aligned healthcare ecosystem to patients that expands EinsteinRx^™ 's technological capabilities into medical, laboratory and wearables fields through a proprietary blockchain, leveraging unique drug-adjunct products to tailor patient-specific solutions through the Health Lives Here app, initially targeting GLP-1-associated muscle loss and Long COVID patient bases. The Company intends to leverage Health Lives Here's unique patient-engagement infrastructure to consolidate electronic health data into our proprietary health-centered blockchain infrastructure to enable patients to participate in data transaction revenue, reduce data friction for providers, and allow for tailored clinical trial offerings of both prescription drugs and/or proprietary nutraceutical products for patients seeking to reach specific health goals.

"Today's announcement is the start of a new chapter in healthcare as we lay the groundwork for patients being able to seize control of their health data," said Gerald Commissiong, Gerald E. Commissiong, Interim Co-CEO of Wellgistics Health. "From the pending launch of our digital platform under the consumer Health Lives Here app, to expanding EinsteinRx AI technology into new medical fields to help consolidate data access for patients, providers, pharmacists, pharmaceutical manufacturers and payors/PBMs, DataMeds AI is building a more cohesive digital health environment that allows for greater efficiency and better health outcomes by breaking down the data sharing barriers that exist in our healthcare system today."

For more information about DataMeds AI, Inc. visit their website or contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com or at 212-805-3024.

About DataMeds AI, Inc.

DataMeds AI, Inc., (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx^™ and blockchain-enabled smart contacts platform PharmacyChain^™ into the Health Lives Here Mobile application and Tollo Health. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the proposed corporate name change to DataMeds AI, Inc.; the proposed rebranding of the Company's Pharmacy and Pharmacy Services division as Corexa Health; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the anticipated timing, structure, terms and completion of such transaction; the satisfaction or waiver of closing conditions; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the proposed name change may not be approved by stockholders or otherwise completed; the risk that the proposed transaction may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company's liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Wellgistics Investor Contact

Investor Relations: IR@wellgisticshealth.com

RUBENSTEIN PUBLIC RELATIONS
CONTACT: JAMES LAMBERT 212-805-3024
JLAMBERT@RUBENSTEINPR.COM

View original content to download multimedia:https://www.prnewswire.com/news-releases/wellgistics-health-inc-officially-changes-corporate-name-to-datameds-ai-inc-302830904.html

SOURCE DataMeds AI, Inc.

FAQ

What corporate name change did Wellgistics Health (NASDAQ:WGRX) announce to investors in July 2026?

Wellgistics Health announced it has officially changed its corporate name to DataMeds AI, Inc.. According to DataMeds, the rebranding reflects its focus on an AI-integrated, vertically aligned healthcare ecosystem centered on patient control and monetization of electronic health data through its Health Lives Here platform.

When will DataMeds AI start trading under the new stock symbol MEDS on NASDAQ?

DataMeds AI will begin trading under the ticker symbol MEDS on the NASDAQ Capital Market on July 22, 2026. According to DataMeds, this follows completion of its name change from Wellgistics Health, previously listed under the symbol WGRX, to support its updated health IT strategy.

What is the business focus of DataMeds AI (NASDAQ:MEDS) after its rebranding from Wellgistics Health?

DataMeds AI focuses on a vertically integrated health IT ecosystem combining AI, pharmacy, pharmaceutical-adjacent and telemedicine units. According to DataMeds, its EinsteinRx AI and PharmacyChain blockchain technologies are integrated into the Health Lives Here app to consolidate patient data and improve digital health experiences.

How does DataMeds AI plan to use AI and blockchain in its Health Lives Here app?

DataMeds AI plans to extend its EinsteinRx AI platform and PharmacyChain blockchain into the Health Lives Here app. According to DataMeds, this aims to consolidate health data, enable patient participation in data-transaction revenue, reduce provider data friction, and support tailored clinical trial and treatment offerings.

Which patient groups is DataMeds AI initially targeting with its Health Lives Here ecosystem?

DataMeds AI is initially targeting patients experiencing GLP-1-associated muscle loss and those with Long COVID. According to DataMeds, its ecosystem uses AI, blockchain and drug-adjunct products to develop patient-specific solutions and tailored offerings delivered through the Health Lives Here mobile application.

How can investors and stakeholders contact DataMeds AI (formerly Wellgistics Health) for more information?

Investors can contact Wellgistics investor relations at IR@wellgisticshealth.com. According to DataMeds, media and stakeholder inquiries may be directed to James Lambert at Rubenstein Public Relations via jlambert@rubensteinpr.com or phone 212-805-3024 for additional corporate and platform details.